SAN DIEGO, June 12, 2013 /PRNewswire/ -- Freedom Meditech, Inc., a medical device company commercializing non-invasive ophthalmic technologies for the detection of disease and management of patient health, today announced the appointment of Paul M. Karpecki, OD, FAAO, to the Scientific Advisory Board. Freedom Meditech also announced that the company will be providing free demonstrations of the ClearPath DS-120, an FDA cleared device for measuring autofluorescence in the lens of the eye, at the 116th Annual AOA Congress & 43rd Annual AOSA Conference being held in San DiegoJune 26-30. The Company will be located at booths 1146 and 1148.
"Freedom Meditech is innovating the routine optometry visit through the introduction of new technologies that enable optometrists to advance their patient's overall health," said Dr. Karpecki. "I am joining the scientific advisory board at an exciting time for the company as it prepares to introduce optometrists to ClearPath DS-120. Detecting autofluorescence in the crystalline lens of the eye, which has been tied to biomarkers associated with diabetes, represents an important and valuable new health offering optometrists can consider during an eye exam."
Dr. Karpecki received his doctor of optometry degree from Indiana University and completed a fellowship in cornea and refractive surgery at Hunkeler Eye Centers in affiliation with the Pennsylvania College of Optometry. He currently works in corneal services, heads the ocular surface disease clinic and is director of clinical research at the Koffler Vision Group in Lexington, Kentucky. Dr. Karpecki was one of two optometrists appointed to the Delphi International Society at Wilmer-Johns Hopkins, which included the top 25 dry eye experts in the world and the National Eye Institute's Dry Eye Committee to provide insights around dry eye and women. A noted educator and author, Dr. Karpecki is the Chief Medical Editor and Vice President of clinical content for the Review of Optometry Journal. He also serves on the board for the charitable organization Optometry Giving Sight.
Dr. Karpecki has lectured in over 400 symposia covering four continents. He has also served as past president of the Optometric Council on Refractive Technology, Chair of the Refractive Surgery Advisory Board to the American Optometric Association (AOA), Chairman of the Topical Interest Group in Refractive Surgery, Chairman of the American Society of Cataract and Refractive Surgeon's Task Force on the Integrated Eyecare Delivery System, Chairman of the Kentucky Optometric Association Education Committee and the AOA Congress Education Committee. Prior to assuming the position of Chief Medical Editor of the Review of Optometry Journal, he served on seven professional journal editorial boards.
About ClearPath DS-120
The ClearPath DS-120 Lens Fluorescence Biomicroscope is cleared by FDA as a tool for the measurement of autofluorescence by scanning the crystalline lens of the eye with a blue light. In independent scientific studies published in peer-reviewed journals, elevated autofluorescence measurements have been linked to high levels of advanced glycosylated end products which accumulate as a result of the aging process and the presence of systemic disease.
The ClearPath scan is pain free, takes just six seconds and produces an immediate, quantitative result available to the patent and healthcare provider. Unlike some eye exams, the scan does not require dilation or other special preparation by the patient. The ClearPath is completely non-invasive and does not require a blood draw to produce a result.
About Freedom Meditech
Freedom Meditech, Inc. is a medical device company focused on the commercialization of novel ophthalmic technologies for the detection of disease and management of patient health. The company has received FDA clearance for its first product, ClearPath DS-120, a non-invasive tool for the measurement of autofluorescence in the eye. I-SugarX is the company's second product currently in development as a non-invasive monitor that measures glucose levels in the aqueous of the eye for people with diabetes. The company maintains corporate and engineering operations in San Diego, CA with supporting research and development activities throughout the state of Ohio. For more information, visit www.freedom-meditech.com or find us on Twitter, Facebook and LinkedIn.
SOURCE Freedom Meditech